Current status of human papillomavirus vaccination

Current Opinion in Oncology

Volumn 27, Issue 5, 2015, Pages 399-404

  Brotherton, Julia M L ^a,b   Ogilvie, Gina S ^c  

^a National HPV Vaccination Program Register   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Dose schedules; Human papillomavirus; Male vaccination; Nine valent HPV vaccine; Vaccination; Vaccine effectiveness

Indexed keywords

WART VIRUS VACCINE;

ANUS CANCER; CLINICAL EFFECTIVENESS; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; GROUPS BY AGE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; MEN WHO HAVE SEX WITH MEN; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; PENIS CANCER; POPULATION RESEARCH; PRECANCER; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX DISEASE; VACCINATION; WART VIRUS; ADOLESCENT; ADULT; COMPLICATION; COST BENEFIT ANALYSIS; FEMALE; IMMUNOLOGY; MALE; MASS IMMUNIZATION; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PRACTICE GUIDELINE; PROGRAM EVALUATION; UTERINE CERVICAL NEOPLASMS; VIROLOGY; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; COST-BENEFIT ANALYSIS; FEMALE; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; MALE; MASS VACCINATION; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PRACTICE GUIDELINES AS TOPIC; PROGRAM EVALUATION; UTERINE CERVICAL NEOPLASMS; WORLD HEALTH ORGANIZATION;

EID: 84942565655     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000211     Document Type: Review

References (39)

1. Li N, Franceschi S, Howell-Jones R, et al. Human papillomaviru s type distribution in 30 848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2010; 128:927-935.
2. Forman D, de Martel C, L acey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30 (Suppl 5):F12-F23.
3. Kocjan BJ, Gale N, Hocevar Boltezar I, et al. Identical human papillom avirus (HPV) genomic variants persist in recurrent respiratory papillomatosis for up to 22 years. J Infect Dis 2012; 207:583-587.
4. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30 (Suppl 5):F123-F138.
5. David MP, Van Herck K, Hardt K, et al. Long-term persistence of anti-HPV-16 and-18 antibodies induced by vaccination with the AS04-Adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol 2009; 115 (3 Suppl):S1-S6.
6. Macartney KK, Chiu C, Georgousakis M, Brotherton JM. Safety of human papillomavirus vaccines: a review. Drug Saf 2013; 36:393-412.
7. Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, et al. Autoimmune, neurological, and venous thromboembol ic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ (Clin Res Ed) 2013; 347:f5906.
8. Global Advisory Committee on Va ccine Safety Statement on the continued safety of HPV vaccination. 12 March 2014 ://www.who.int/vaccine-safety/committee/topics/hpv/GACVS-Statement-HPV-12-Mar-2014.pdf?ua= 1 Accessed 26/03/15.
9. Drolet M, Benard E, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-Analysis. Lancet Infect Dis 2015; 15:565-580. This is the first meta-Analysis of the effectiveness of HPV vaccination as implemented globally and indicates that the vaccines are already reducing infection and disease, with higher coverage associated with larger impacts and evidence of herd protection .
10. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11:39-44.
11. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ (Clin Res Ed) 2013; 346:f2032.
12. Chow EP, Read TR, Wigan R, et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infec t 2015; 91:214-219.
13. Smith MA, Liu B,McIntyre P, et al. Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a National Human Papillomavirus V accination Program: Analysis of Routinely Collected National Hospital Data. J Infect Dis 2014; 211:91-99. This is a significant analysis which is the first to document an impact of HPV vaccination in an Indigenous population. Genital wart-related admissions declined equally in Indigenous Australians as in non-Indigenous Australians.
14. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women foll owing HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys. J Infect Dis 2013; 208:385-393.
15. Sonnenberg P, Clifton S, Beddows S, et al. Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet 2013; 382:1795-1806.
16. Brothert on JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377:2085-2092.
17. Brotherton JMLB, Sa ville AM, May CL, et al. Human papillomavirus vaccination is changing the epidemiology of high-grade cervical lesions in Australia. Cancer Causes Control 2015; 26:953-954. This article documents ongoing declines in Austr alia in high-grade cervical lesions, now extending into the 20-24-year-old age group, 7 years into the vaccination program.
18. Frisch M, Smith E, Grulich A, Johansen C. Cancer in a population-based cohort of men and women in registered homosexual partnerships. Am J Epidemiol 2003; 157:966-972.
19. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011; 364:401-411.
20. Palefsky JM , Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365:1576-1585.
21. Georgousakis M, Jayasinghe S, Brothert on J, et al. Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study. Lancet Infect Dis 2012; 12:627-634.
22. Canfell K, Chesson H, Kulasingam SL, et al. Modeling preventive strategies against human papillomavirus-related disease in developed countries. Vaccine 2012; 30 (Suppl 5):F157-F167.
23. Stokley S, Jeyarajah J, Yankey D, et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014: United States. MMWR Morbidity and mortality weekly report 2014; 63:620-624.
24. Stanley MA, Sudenga SL, Giuliano AR. Alternative dosage schedules with HPV virus-like particle vaccines. Expert Rev Vaccines 2014; 13:1027-1038. This is an outstanding review article describing in-depth the evidence around decisions to consider implementing two-dose vaccination strategies for young adolescents.
25. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013; 309:1793-1802.
26. Romanowski B, Schwarz TF, Ferguson LM, et al. Immune respo nse to the HPV-16/18 AS04-Adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: Results from a randomized study. Hum Vaccin Immunother 2014; 10:1155-1165.
27. Smolen KK, Gelinas L, Franzen L, et al. Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine 2012; 30:3572-3579.
28. De Carvalh o N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-Adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010; 28:6247-6255.
29. Ro whani-Rahbar A, Mao C, Hughes JP, et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 2009; 27:5612-5619.
30. De Vincenzo R, Conte C, Ri cci C, et al. Long-term efficacy and safety of human papillomavirus vaccination. Int J Women's Health 2014; 6:999-1010.
31. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-princ iple evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011; 103:1444-1451.
32. Safaeian M, Porras C, Pan Y, et al. Durable antibody respons es following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Philadelphia, PA) 2013; 6:1242-1250.
33. Schiller JT, Lowy DR. Raising expectations for subunit vaccine. J Infect Dis 2014; 211:1373-1375. A fascinating piece from two of the joint discoverers of the science underpinning HPV vaccines discussing why one-dose HPV vaccination strategy is worth evaluating.
34. World Health Organisation position paper on HPV vaccines. October 2014. WER 43, 89: 465-492. Updated WHO position statement on the global use of HPV vaccines.
35. Jit M, Bri sson M, Laprise JF, Choi Y. Comparing two-dose and three-dose human papillomavirus vaccine schedules: cost-effectiveness analysis based on transmission model. BMJ 2015; 350:g7584.
36. Brotherton J. Two or three doses of human papillomavirus vaccine BMJ (Clin Res Ed) 2015; 350:g7778.
37. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and int raepithelial neoplasia in women. New Engl J Med 2015; 372:711-723. The randomized trial of the nine-valent vaccine compared with the quadrivalent vaccine demonstrating high efficacy and immunogenicity.
38. Drole t M, Laprise JF, Boily MC, et al. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer 2014; 134:2264-2268.
39. Petrosky E, Bocchini JA Jr., Har iri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2015; 64:300-304.